Workflow
Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results

Core Insights - Generation Bio Co. has demonstrated the ability of its cell-targeted lipid nanoparticle (ctLNP) system to selectively deliver siRNA to T cells in non-human primates, marking a significant advancement in genetic medicine for T cell-driven autoimmune diseases [1][2][3] Financial Position - As of June 30, 2025, the company reported a cash balance of $141.4 million, down from $185.2 million at the end of 2024 [11][14] - Research and development (R&D) expenses for Q2 2025 were $15.5 million, a decrease from $16.4 million in Q2 2024 [11][16] - General and administrative (G&A) expenses were $7.7 million for Q2 2025, down from $9.5 million in the same quarter of the previous year [11][16] - The net loss for Q2 2025 was $20.9 million, or $3.12 per share, compared to a net loss of $20.4 million, or $3.07 per share, in Q2 2024 [11][16] Strategic Developments - The company is exploring strategic alternatives to maximize the value of its delivery system and potential therapeutics, including options such as acquisition, merger, or sale of assets [5][6] - A significant workforce reduction of approximately 90% is planned as part of a strategic restructuring process, expected to begin in mid-August 2025 and conclude by the end of October 2025 [7][6] Research and Development Highlights - The ctLNP system has shown significant knockdown of beta-2 microglobulin in T cells over three weeks in a non-human primate study, indicating its selective and potent delivery capabilities [3][4] - Lead siRNA candidates have demonstrated effective knockdown of LAT1 and VAV1, which are relevant targets for T cell-driven autoimmune diseases [4][6]